The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: an European analysis

European Heart Journal, 05/31/2012

These results suggest that primary prophylactic ICD therapy in patients with a left ventricular ejection fraction <40% and ischaemic or non–ischaemic heart disease is cost–effective in the European setting.

Print Article Summary Cat 2 CME Report